Steven Katz, M.D., FACS

Dr. Steven Katz brings over 15 years of expertise in clinical oncology, translational science, and the development of immunotherapies, including cell therapies for solid tumors in both the U.S. and Japan. He has successfully led multiple clinical trials, established immune correlative biospecimen programs, secured IND clearance for complex drug-device trials, and played a key role in supporting a Nasdaq listing.

‍

Dr. Katz’s work includes pioneering novel immunotherapy approaches for liver and pancreatic tumors, addressing key challenges in the treatment of solid tumors. At Shinobi, he leads translational science and clinical operations, driving innovative strategies to overcome barriers in solid tumor therapies and accelerate clinical progress.